Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1.

Summary, in English

Secretory leukocyte protease inhibitor (SLPI) is a protein with anti-protease and antimicrobial properties that is constitutively secreted from the airway epithelium. The importance of maintaining a balance between proteases and anti-proteases, and robust innate defence mechanisms in the airways, is exemplified by inflammatory lung conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Both conditions present with a high protease burden in the airways which leads to tissue destruction. These patients also have an impaired innate immune system in the lungs with bacterial colonization and frequent airway infections. Moreover, both diseases are associated with airway hypoxia due to inflammation and mucus plugs. The aim of the present study was to investigate the role of hypoxia on SLPI production from the airway epithelium.

• Author: Lisa Påhlman; Annika Jögi; Magnus Gram; Michiko Mori; Arne Egesten
• Department/s: Infection Medicine (BMC); Division of Translational Cancer Research; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation; Airway Inflammation and Immunology; Respiratory Medicine, Allergology, and Palliative Medicine
• Publishing year: 2015
• Language: English
• Publication/Series: BMC Pulmonary Medicine
• Volume: 15
• Issue: 1
• Full text: - 502 kB; Download statistics
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25778525?dopt=Abstract; http://dx.doi.org/10.1186/s12890-015-0016-0
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Respiratory Medicine and Allergy
• Status: Published
• Research group: Airway Inflammation and Immunology
• ISBN/ISSN/Other: ISSN: 1471-2466